Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1672-1676

  Liu, Ping ^a   Ruhnke, Markus ^b   Meersseman, Wouter ^c   Paiva, José Artur ^d   Kantecki, Michal ^a   Damle, Bharat ^a  

^a PFIZER INC   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Centro Hospitalar Universitário de São João   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CALCULATION; CANDIDEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG CLEARANCE; FEMALE; HUMAN; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; CRITICAL ILLNESS; ECHINOCANDINS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84875170170     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02139-12     Document Type: Article

References (19)

1. Vazquez JA. 2010. Invasive fungal infections in the intensive care unit. Semin. Respir. Crit. Care Med. 31:79-86.
2. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in the ICU Study (EPIC II) Group of Investigators. 2011. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 39:665-670.
3. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. 2007. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J. Crit. Care 22:237-244.
4. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. 2009. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit. Care 13:R159. doi:10.1186/cc8117.
5. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. 2011. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit. Care 15:R253. doi: 10.1186/cc10514.
6. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza Crespo R, Kullberg BJ. 2009. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med. 35:55-62.
7. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
8. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group (EFISG). 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18:19-37.
9. Kofla G, Ruhnke M. 2011. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur. J. Med. Res. 16:159-166.
10. Dowell JA, Stogniew M, Krause D, Damle B. 2007. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol. 47:461-470.
11. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. 2009. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother. 53:1149-1156.
12. Ruhnke M, Paiva JA, Meersseman W, Pachl J, Grigoras I, Sganga G, Menichetti F, Montravers P, Auzinger G, Dimopoulos G, Sa MB, Miller PJ, Marcek T, Kantecki M. 2012. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. Clin. Microbiol. Infect. 18:680-687.
13. Alebic-Kolbah T, Modesitt MS. 2012. Anidulafungin-challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies. Anal. Bioanal. Chem. 404:2043-2055.
14. Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, Weigand MA. 2007. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob. Chemother. 60:100-106.
15. Liu P. 2013. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections. Antimicrob. Agents Chemother. 57:466-474.
16. Pfizer. 2010. Eraxis (anidulafungin) package insert. Pfizer, New York, NY.
17. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. 2007. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J. Clin. Pharmacol. 47:305-314.
18. Pascual AA, Senn L, Bolay S, Rochat B, Eggimann P, Ksontini R, Buclin T, Bille J, Calandra T, Marchetti O. 2007. Low total plasma concentration of caspofungin in surgical intensive care unit patients, abstr M2025, p 465. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother.
19. Hanley MJ, Abernethy DR, Greenblatt DJ. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet. 49:71-87.